Previous 10 | Next 10 |
SAN FRANCISCO, July 21, 2022 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology,” Nasdaq: OLMA) today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to OP-1250, the Company's novel, oral ...
BMEZ has been getting hit significantly, with the biotech and growth space moving sharply lower. Despite these pressures, I believe that BMEZ is attractive given its current discount and selloff. With our recent update on BlackRock Science & Technology Trust II, the fund's dis...
Olema Pharmaceuticals (NASDAQ:OLMA) on Thursday announced a clinical update for its lead candidate OP-1250 for the treatment of metastatic breast cancer. In its phase 1b dose expansion of OP-1250 as a monotherapy, OLMA said it observed favorable tolerability in the 30 patients enrolled. OLMA ...
Favorable tolerability with no grade 3/4 neutropenia and encouraging anti-tumor activity across Phase 1b monotherapy expansion Combinability with CDK4/6i palbociclib demonstrated across initial dose escalation cohorts, including no dose limiting toxicities and no induced metab...
SAN FRANCISCO, June 09, 2022 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology,” Nasdaq: OLMA) and Aurigene Discovery Technologies Limited (“Aurigene”) today announced an exclusive global license agreement to research, ...
SAN FRANCISCO, May 24, 2022 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology,” Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted therapies for women...
Olema Pharmaceuticals press release (NASDAQ:OLMA): Q1 GAAP EPS of -$0.58. Cash, cash equivalents and marketable securities as of March 31, 2022, were $267.9 million. For further details see: Olema Pharmaceuticals GAAP EPS of -$0.58
Phase 1/2 trial of OP-1250 continues to enroll patients in the dose expansion stage, with selection of Recommended Phase 2 Dose expected in Q2 2022 Phase 1b combination study with palbociclib ongoing; Additional combination trials with CDK4/6 and PI3K α inhibitors...
Gainers: Checkmate Pharmaceuticals (CMPI) +332%. Sono Group (SEV) +66%. ToughBuilt Industries (TBLT) +55%. Petros Pharmaceuticals (PTPI) +40%. Axsome Therapeutics (AXSM) +25%. Cyren (CYRN) +22%. Super Micro Computer (SMCI) +21%. Pulse Biosciences (PLSE) +18%. Annexon (ANNX) +18%. Olema Pharma...
SAN FRANCISCO, April 18, 2022 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema,” “Olema Oncology” or the “Company,” Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of ...
News, Short Squeeze, Breakout and More Instantly...
Olema Pharmaceuticals Inc. Company Name:
OLMA Stock Symbol:
NASDAQ Market:
Olema Pharmaceuticals Inc. Website:
2024-06-13 17:30:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-06-04 15:30:03 ET Oppenheimer analyst issues OUTPERFORM recommendation for OLMA on June 4, 2024 02:10PM ET. The previous analyst recommendation was Outperform. OLMA was trading at $14.4 at issue of the analyst recommendation. The overall analyst consensus : BUY. ...
Olema Pharmaceuticals, Inc. (NASDAQ: OLMA) is one of today's top gainers. The company's shares have moved 17.73% on the day to $13.84. Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's ...